Indacaterol

Indacaterol
Clinical data
Trade names	Onbrez, Arcapta
AHFS/Drugs.com	International Drug Names
License data	EU EMA: by INN; US DailyMed: Indacaterol;
Pregnancy; category	AU: B3; ;
Routes of; administration	Inhalation
ATC code	R03AC18 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
CAS Number	312753-06-3 ;
PubChem CID	6433117;
IUPHAR/BPS	7455;
ChemSpider	5293751 ;
UNII	8OR09251MQ;
KEGG	D09318 ;
ChEBI	CHEBI:68575 ;
ChEMBL	ChEMBL1095777 ;
CompTox Dashboard (EPA)	DTXSID90185198 ;
ECHA InfoCard	100.218.577
Chemical and physical data
Formula	C24H28N2O3
Molar mass	392.499 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4/C=C\c1c(c(O)ccc1[C@@H](O)CNC3Cc2cc(c(cc2C3)CC)CC)N4;
	InChI InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1 ; Key:QZZUEBNBZAPZLX-QFIPXVFZSA-N ;
	(what is this?) (verify)

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist^[5] developed by Novartis. It needs to be taken only once a day,^[6] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.

Medical uses

A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.^[7]

History

It was approved by the European Medicines Agency (EMA) under the brand name Onbrez Breezhaler on November 30, 2009,^[8] and by the United States Food and Drug Administration (FDA), under the brand name Arcapta Neohaler, on July 1, 2011.^[9]^[10] In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler to Sunovion Pharmaceuticals.^[11]

References

^ "Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011". DailyMed. 1 April 2020. Retrieved 14 June 2021.
^ "Onbrez Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
^ "Oslif Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
^ "Hirobriz Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
^ Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567. S2CID 11930383.
^ Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (May 2007). "Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma". Eur. Respir. J. 29 (5): 871–8. doi:10.1183/09031936.00060006. PMID 17251236.
^ Geake, James B (2015). "Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease". Reviews. 1 (3): CD010139. doi:10.1002/14651858.CD010139.pub2. PMC 6464646. PMID 25575340.
^ European Public Assessment Report for Onbrez Breezhaler Archived 2010-01-16 at the Wayback Machine
^ "FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease" (Press release). U.S. Food and Drug Administration. 2011-07-01. Archived from the original on 2011-07-03. Retrieved 2011-07-02.
^ "Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383". U.S. Food and Drug Administration. 13 August 2013. Retrieved 14 June 2021.
^ Faulkner, Sarah (22 December 2016). "Sunovion, Novartis ink licensing deal for inhaled COPD drugs". Drug Delivery Business.

[1] "Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011". DailyMed. 1 April 2020. Retrieved 14 June 2021.

[2] "Onbrez Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.

[3] "Oslif Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.

[4] "Hirobriz Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.

[pmid16022567-5] Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567. S2CID 11930383.

[pmid17251236-6] Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (May 2007). "Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma". Eur. Respir. J. 29 (5): 871–8. doi:10.1183/09031936.00060006. PMID 17251236.

[7] Geake, James B (2015). "Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease". Reviews. 1 (3): CD010139. doi:10.1002/14651858.CD010139.pub2. PMC 6464646. PMID 25575340.

[8] European Public Assessment Report for Onbrez Breezhaler Archived 2010-01-16 at the Wayback Machine

[9] "FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease" (Press release). U.S. Food and Drug Administration. 2011-07-01. Archived from the original on 2011-07-03. Retrieved 2011-07-02.

[10] "Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383". U.S. Food and Drug Administration. 13 August 2013. Retrieved 14 June 2021.

[11] Faulkner, Sarah (22 December 2016). "Sunovion, Novartis ink licensing deal for inhaled COPD drugs". Drug Delivery Business.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]